Alterity Therapeutics Reports Change in Director Marks\' Interest

Alterity Therapeutics Limited, a development-stage biotechnology company, filed a Form 6-K on September 2, 2026, with the SEC to report a change in a director\'s interest. Specifically, the filing includes Exhibit 99.1, which is a "Change of Director\'s Interest Notice" for Director Marks. This regulatory filing is a standard requirement for foreign private issuers to disclose updates regarding the shareholdings or financial interests of their board members. The report was signed by Julian Babarczy, the Chairman of Alterity Therapeutics. The filing is also incorporated by reference into several of the company\'s existing Registration Statements on Form S-8 and Form F-3. No clinical data, financial results, or corporate strategy updates were included in this specific disclosure. The document serves primarily as a notification of insider transactional activity or interest adjustments as required by Australian and U.S. securities regulations.